ES2051920T3 - Una composicion farmaceutica y su procedimiento de preparacion. - Google Patents
Una composicion farmaceutica y su procedimiento de preparacion.Info
- Publication number
- ES2051920T3 ES2051920T3 ES89109381T ES89109381T ES2051920T3 ES 2051920 T3 ES2051920 T3 ES 2051920T3 ES 89109381 T ES89109381 T ES 89109381T ES 89109381 T ES89109381 T ES 89109381T ES 2051920 T3 ES2051920 T3 ES 2051920T3
- Authority
- ES
- Spain
- Prior art keywords
- pharmaceutical composition
- preparation procedure
- dimetilo
- sucinato
- fenilmetil
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/665—Phosphorus compounds having oxygen as a ring hetero atom, e.g. fosfomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Diabetes (AREA)
- Inorganic Chemistry (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Rheumatology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP13226288 | 1988-05-30 | ||
| JP1050471A JP2528706B2 (ja) | 1988-05-30 | 1989-03-02 | ジヒドロピリジン化合物の製剤組成物 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2051920T3 true ES2051920T3 (es) | 1994-07-01 |
Family
ID=26390939
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES89109381T Expired - Lifetime ES2051920T3 (es) | 1988-05-30 | 1989-05-24 | Una composicion farmaceutica y su procedimiento de preparacion. |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US4983593A (enExample) |
| EP (1) | EP0344603B1 (enExample) |
| JP (1) | JP2528706B2 (enExample) |
| CA (1) | CA1332152C (enExample) |
| DE (1) | DE68900356D1 (enExample) |
| ES (1) | ES2051920T3 (enExample) |
| GR (1) | GR3003615T3 (enExample) |
| NZ (1) | NZ229309A (enExample) |
Families Citing this family (56)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW212139B (enExample) * | 1991-04-15 | 1993-09-01 | Yamanouchi Pharma Co Ltd | |
| US5455046A (en) * | 1993-09-09 | 1995-10-03 | Edward Mendell Co., Inc. | Sustained release heterodisperse hydrogel systems for insoluble drugs |
| US6726930B1 (en) | 1993-09-09 | 2004-04-27 | Penwest Pharmaceuticals Co. | Sustained release heterodisperse hydrogel systems for insoluble drugs |
| US5773025A (en) | 1993-09-09 | 1998-06-30 | Edward Mendell Co., Inc. | Sustained release heterodisperse hydrogel systems--amorphous drugs |
| TW487582B (en) * | 1995-08-11 | 2002-05-21 | Nissan Chemical Ind Ltd | Method for converting sparingly water-soluble medical substance to amorphous state |
| KR100457273B1 (ko) * | 1996-03-18 | 2005-04-08 | 닛산 가가쿠 고교 가부시키 가이샤 | 에포니디핀염산염제제의제조방법 |
| EP0859603B1 (en) | 1996-07-08 | 2008-12-17 | Penwest Pharmaceuticals Co. | Sustained release matrix for high-dose insoluble drugs |
| DK0901786T3 (da) | 1997-08-11 | 2007-10-08 | Pfizer Prod Inc | Faste farmaceutiske dispersioner med foröget biotilgængelighed |
| EP1745774A3 (en) | 1997-08-11 | 2007-04-11 | Pfizer Products Inc. | Solid pharmaceutical dispersions with enhanced bioavailability |
| US6056977A (en) | 1997-10-15 | 2000-05-02 | Edward Mendell Co., Inc. | Once-a-day controlled release sulfonylurea formulation |
| US6350786B1 (en) † | 1998-09-22 | 2002-02-26 | Hoffmann-La Roche Inc. | Stable complexes of poorly soluble compounds in ionic polymers |
| ATE400251T1 (de) | 1999-02-09 | 2008-07-15 | Pfizer Prod Inc | Zusammensetzungen basischer arzneistoffe mit verbesserter bioverfügbarkeit |
| EP1027886B1 (en) * | 1999-02-10 | 2008-07-09 | Pfizer Products Inc. | Pharmaceutical solid dispersions |
| ATE404178T1 (de) * | 1999-02-10 | 2008-08-15 | Pfizer Prod Inc | Vorrichtung mit matrixgesteuerter wirkstofffreisetzung |
| EP1027888B1 (en) * | 1999-02-10 | 2009-06-10 | Pfizer Products Inc. | Osmotic system for delivery of solid amorphous dispersions of drugs |
| US6706283B1 (en) | 1999-02-10 | 2004-03-16 | Pfizer Inc | Controlled release by extrusion of solid amorphous dispersions of drugs |
| KR100463496B1 (ko) * | 1999-09-30 | 2005-01-06 | 펜웨스트 파머슈티칼즈 컴파니 | 고가용성 약물용 서방성 메트리스 시스템 |
| JP2003518038A (ja) * | 1999-12-20 | 2003-06-03 | ニコラス， ジェイ カークホフ， | 流動床噴霧乾燥によるナノ粒子製造方法 |
| DZ3227A1 (fr) | 1999-12-23 | 2001-07-05 | Pfizer Prod Inc | Compositions pharmaceutiques fournissant des concentrations de medicaments ameliorees |
| US7115279B2 (en) | 2000-08-03 | 2006-10-03 | Curatolo William J | Pharmaceutical compositions of cholesteryl ester transfer protein inhibitors |
| AU2002212102A1 (en) * | 2000-11-08 | 2002-05-21 | Aeromatic-Fielder Ag | A process for production of particles for pharmaceutical compositions having increased bioavailability |
| DE10058772A1 (de) * | 2000-11-27 | 2002-06-06 | Falk Pharma Gmbh | Verfahren zur Herstellung leicht löslicher Arzneimittelformulierungen und entsprechende Formulierungen |
| MXPA03011935A (es) * | 2001-06-22 | 2004-03-26 | Pfizer Prod Inc | Composiciones farmaceuticas que contienen conjuntos de polimero y farmaco. |
| MXPA03011784A (es) | 2001-06-22 | 2004-04-02 | Pfizer Prod Inc | Composiciones farmaceuticas de dispersiones de farmacos y polimeros neutros. |
| AR038375A1 (es) * | 2002-02-01 | 2005-01-12 | Pfizer Prod Inc | Composiciones farmaceuticas de inhibidores de la proteina de transferencia de esteres de colesterilo |
| WO2005117834A1 (en) * | 2004-05-27 | 2005-12-15 | Janssen Pharmaceutica N.V. | Solid dispersions of a basic drug compound and a polymer containing acidic groups |
| MXPA06013891A (es) | 2004-05-28 | 2007-01-26 | Pfizer Prod Inc | Composiciones farmaceuticas con comportamiento potenciado. |
| US20080096924A1 (en) * | 2004-12-17 | 2008-04-24 | Ono Pharmaceutical Co., Ltd. | Amorphous Composition |
| WO2007029660A1 (ja) * | 2005-09-06 | 2007-03-15 | Astellas Pharma Inc. | 腸溶性基剤が表面に吸着した難溶性薬物の微小粒子 |
| WO2008063888A2 (en) | 2006-11-22 | 2008-05-29 | Plexxikon, Inc. | Compounds modulating c-fms and/or c-kit activity and uses therefor |
| US20100190777A1 (en) | 2007-07-17 | 2010-07-29 | Plexxikon Inc. | Compounds and methods for kinase modulation, and indications therefor |
| EP2191830A4 (en) | 2007-09-21 | 2011-11-23 | Shionogi & Co | SOLID PREPARATION COMPRISING A NPYY5 RECEPTOR ANTAGONIST |
| US9149434B2 (en) * | 2007-12-03 | 2015-10-06 | Tomita Pharmaceutical Co., Ltd. | Core particle for pharmaceutical preparation |
| EP2291079B1 (en) * | 2008-05-14 | 2013-04-24 | Merck Sharp & Dohme Corp. | Formulations for cathepsin k inhibitors |
| HUE027598T2 (en) | 2009-04-03 | 2016-10-28 | Hoffmann La Roche | Propane-1-sulfonic acid {3- [5- (4-chlorophenyl) -1H-pyrrolo [2,3-B] pyridine-3-carbonyl] -2,4-difluorophenyl} amide compositions and their uses |
| US8329724B2 (en) | 2009-08-03 | 2012-12-11 | Hoffmann-La Roche Inc. | Process for the manufacture of pharmaceutically active compounds |
| WO2011031620A1 (en) * | 2009-09-11 | 2011-03-17 | Transtech Pharma, Inc. | Solid compositions comprising an oxadiazoanthracene compound and methods of making and using the same |
| ES2633317T3 (es) | 2009-11-06 | 2017-09-20 | Plexxikon, Inc. | Compuestos y métodos para la modulación de quinasas, e indicaciones para ello |
| JP5792807B2 (ja) | 2010-06-14 | 2015-10-14 | ダウ グローバル テクノロジーズ エルエルシー | アセテートおよびサクシネートの置換が向上されたヒドロキシプロピルメチルセルロースアセテートサクシネート |
| MA34948B1 (fr) | 2011-02-07 | 2014-03-01 | Plexxikon Inc | Composes et procedes de modulation de kinase, et leurs indications |
| TWI558702B (zh) | 2011-02-21 | 2016-11-21 | 普雷辛肯公司 | 醫藥活性物質的固態形式 |
| EP2654726A1 (en) | 2011-03-08 | 2013-10-30 | Zalicus Pharmaceuticals Ltd. | Solid dispersion formulations and methods of use thereof |
| US9150570B2 (en) | 2012-05-31 | 2015-10-06 | Plexxikon Inc. | Synthesis of heterocyclic compounds |
| EP2837391B1 (en) | 2013-08-12 | 2017-05-10 | Shin-Etsu Chemical Co., Ltd. | Hypromellose acetate succinate for use as hot-melt extrusion carrier, hot-melt extrusion composition, and method for producing hot-melt extrudate |
| EP3089736B1 (en) | 2013-12-31 | 2025-07-23 | Ascendia Pharmaceuticals, LLC | Pharmaceutical compositions for poorly water-soluble compounds |
| AR106018A1 (es) | 2015-08-26 | 2017-12-06 | Achillion Pharmaceuticals Inc | Compuestos de arilo, heteroarilo y heterocíclicos para el tratamiento de trastornos médicos |
| EP3340982B1 (en) | 2015-08-26 | 2021-12-15 | Achillion Pharmaceuticals, Inc. | Compounds for treatment of immune and inflammatory disorders |
| CN109414441A (zh) | 2016-06-27 | 2019-03-01 | 艾其林医药公司 | 治疗医学障碍的喹唑啉和吲哚化合物 |
| KR102632860B1 (ko) | 2017-03-01 | 2024-02-02 | 아칠리온 파르마세우티칼스 인코포레이티드 | 의학적 장애의 치료를 위한 아릴, 헤테로아릴, 및 헤테로사이클릭 약학적 화합물 |
| WO2018175648A1 (en) * | 2017-03-21 | 2018-09-27 | Bioduro, Llc | Gastrointestinal-protective formulations for oral delivery of proteins and peptides |
| US20230022157A1 (en) | 2018-08-20 | 2023-01-26 | Achillion Pharmaceuticals, Inc. | Pharmaceutical compounds for the treatment of complement factor d medical disorders |
| EP3846803A4 (en) | 2018-09-06 | 2022-08-10 | Achillion Pharmaceuticals, Inc. | Macrocyclic compounds for the treatment of medical disorders |
| WO2020081723A1 (en) | 2018-10-16 | 2020-04-23 | Georgia State University Research Foundation, Inc. | Carbon monoxide prodrugs for the treatment of medical disorders |
| CN119837855A (zh) | 2019-12-19 | 2025-04-18 | 乔治亚州大学研究基金会 | 用于治疗细菌感染和增强抗生素的化合物 |
| CN115362162A (zh) | 2020-02-20 | 2022-11-18 | 艾其林医药公司 | 用于治疗补体因子d介导的障碍的杂芳基化合物 |
| CA3193488A1 (en) | 2020-09-23 | 2022-03-31 | Jason Allan Wiles | Pharmaceutical compounds for the treatment of complement mediated disorders |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5948810A (ja) | 1982-09-10 | 1984-03-21 | Sony Corp | 磁性記録体におけるデ−タのマスク及び再生方法 |
| JPS62123117A (ja) | 1985-11-22 | 1987-06-04 | Nippon Chemiphar Co Ltd | 塩酸ニカルジピン経口用組成物 |
| CN1016063B (zh) * | 1986-01-22 | 1992-04-01 | 日产化学工业株式会社 | 二氢吡啶-5-膦酸环亚丙基酯的制备 |
| IL81419A0 (en) * | 1986-01-30 | 1987-08-31 | Syntex Inc | Long acting sustained release pharmaceutical compositions containing dihydropyridines and their preparation |
-
1989
- 1989-03-02 JP JP1050471A patent/JP2528706B2/ja not_active Expired - Lifetime
- 1989-05-24 DE DE8989109381T patent/DE68900356D1/de not_active Expired - Lifetime
- 1989-05-24 ES ES89109381T patent/ES2051920T3/es not_active Expired - Lifetime
- 1989-05-24 EP EP89109381A patent/EP0344603B1/en not_active Expired - Lifetime
- 1989-05-25 CA CA000600631A patent/CA1332152C/en not_active Expired - Lifetime
- 1989-05-26 NZ NZ229309A patent/NZ229309A/en unknown
- 1989-05-30 US US07/358,144 patent/US4983593A/en not_active Expired - Lifetime
-
1992
- 1992-01-22 GR GR920400057T patent/GR3003615T3/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2528706B2 (ja) | 1996-08-28 |
| US4983593A (en) | 1991-01-08 |
| GR3003615T3 (enExample) | 1993-03-16 |
| EP0344603A1 (en) | 1989-12-06 |
| CA1332152C (en) | 1994-09-27 |
| DE68900356D1 (de) | 1991-11-28 |
| EP0344603B1 (en) | 1991-10-23 |
| NZ229309A (en) | 1991-06-25 |
| JPH0249728A (ja) | 1990-02-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BG60102B2 (bg) | Метод за получаване на 5-флуор-2(((4-циклопропил- метокси-2-пиридинил)метил)тионил)-1н-бензимидазол | |
| IT8819693A0 (it) | Apparecchio atto ad operare, in modo pressoche' istantaneo, la distruzione completa dell'ago di siringhe per iniezione, subito dopo il loro impiego. | |
| RU94022479A (ru) | Применение антиэстрогенных соединений, а также фармацевтически приемлемых солей и сольватов для уменьшения концентрации глюкозы в крови, фармацевтический препарат | |
| IT1225440B (it) | Pistone per siringhe che rende automaticamente inoffensivo l'ago ipodermico, all'uopo modificato, dopo l'uso | |
| ITRM940621A0 (it) | "composizione farmaceutica stabilizzata, relativo solvente e procedimento di preparazione" | |
| DK395689A (da) | Pharmaceutisk tilberedning til behandling af diabetes mellitus | |
| DE69011059D1 (de) | Heterozyklische Acylaminothiazolderivate, ihre Herstellung und diese enthaltende pharmazeutische Zubereitungen. | |
| GR1001503B (el) | Μέ?οδος δια την παρασκευή φαρμακευτικών ενώσεων αι οποίαι περιέχουν ως δραστική ουσία καρβονικά οξέα τα οποία περιέχουν ?είον κα?ώς και η χρησιμοποίησις αυτών δια την καταπολέμησιν των ρετροιών. | |
| NO842290L (no) | Fremgangsmaate for fremstilling av preparater inneholdende oralt antidiabetisk aktive stoffer | |
| ES2161697T3 (es) | Peptidos agonistas de amilina y usos de los mismos. | |
| ES2067250T3 (es) | Preparado farmaceutico sin disolventes para administracion oral, con liberacion retardada de la sustancia activa y procedimiento para su fabricacion. | |
| KR910000703A (ko) | 테트라졸 자극성 아미노산 수용체의 길항물질 | |
| PT101725A (pt) | Processo para a preparacao de um composto de diarilo anti-aterosclerotico e de composicoes farmaceuticas que o contem | |
| FI913036A0 (fi) | Terapeutiskt aktiv substituerad benzimidazol och foerfarande foer dess framstaellning. | |
| Kastin et al. | Inhibition of MSH release in frogs by direct application of L-prolyl-L-leucylglycinamide to the pituitary | |
| KR840003415A (ko) | 경구용 당뇨병 치료제의 제조방법 | |
| ATE67406T1 (de) | Nicorandil enthaltende zubereitung zum einspritzen. | |
| AR012997A1 (es) | Uso de 5-[4-[2-(n-metil-n-(2-piridil)amino)etoxi]bencil]tiazolidin-2,4- diona e insulina para la preparacion de medicamentos, y composicionfarmaceutica que los contiene. | |
| FI913034A0 (fi) | Foerening med magsyrainhiberande effekt och foerfarande foer dess framstaellning. | |
| ATE87467T1 (de) | Pharmazeutische zubereitung. | |
| DE3772460D1 (de) | Pharmazeutische zubereitung fuer eine parenterale verabreichung, die calcitonin als wirkstoff enthaelt. | |
| KR940005283A (ko) | 활성 성분으로 글리센틴을 함유하는 약제 | |
| AR012996A1 (es) | Uso de un sensibilizador a la insulina para la preparacion de un medicamento y composicion farmaceutica que comprende dicho sensibilizador. | |
| EA200000141A1 (ru) | Способ лечения диабета тиазолидиндионом и сульфонилмочевиной | |
| NO180269C (no) | Analogifremgangsmåte for fremstilling av terapeutisk akive aminoketonderivater |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG2A | Definitive protection |
Ref document number: 344603 Country of ref document: ES |